Versuchen GOLD - Frei

Lactose India unveils new specialized grades

Chronicle Pharmabiz

|

November 27, 2025

IN a significant boost to India’s pharmaceutical sector, Lactose India Ltd (LIL) has launched a new lineup of specialized lactose grades, marking a pivotal advancement in the country’s domestic production capabilities.

- Our Bureau, Mumbai

Lactose India unveils new specialized grades

Established in 1991 and headquartered along the Vadodara-Ahmedabad Expressway in Poicha, LIL is leveraging its expansive state-of-the-art five-acre facility to deliver high-value high performance lactose products. This move not only expands their product portfolio but also aligns seamlessly with the national vision of “Atma Nirbhar Bharat” (Self-Reliant India) and “Make in India,” reducing the nation’s dependence on imports for critical pharmaceutical excipients.

In keeping with its commitment to responsible growth, Lactose India’s focus on sustainability drives operational excellence — through optimized energy-efficient processes, reduced emissions, conscious material sourcing, wastewater recycling systems to promote greener practices across its product lifecycle. Every batch reflects LIL’s holistic belief that progress and environmental governance must go hand in hand.

Lactose India, a recognized leader in lactose monohydrate production with an installed capacity of 12,000 metric tons per annum - is set to double following a recent acquisition - is a market leader for its regular grades such as 200 Mesh, 125M, 450M, PHA, DC2050, DC60, 80M, 100M, 325M, and IMP variants in milled and sieved forms. These have served both domestic and overseas markets effectively.

The introduction of specialized segments marks a strategic evolution, targeting niche applications in pharmaceuticals, including excipients, APIs, and formulations - all housed within a single campus featuring dedicated production blocks, warehouses, and quality assurance offices, ensuring world class standards in every batch.

New specialized grades: Innovation meets demand

WEITERE GESCHICHTEN VON Chronicle Pharmabiz

Chronicle Pharmabiz

US FDA fortifies alliance with Telangana DCA

A high-level delegation from the US FDA concluded a significant meeting with the DCA in Telangana, two days ago, at the DCA office in Hyderabad.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

India exploring possibilities to expand WHO standards for Indian medicines

INDIA is looking at possibilities to expand the World Health Organisation (WHO) global benchmarking standards for medicines, in order to unify and strengthen the drug regulatory mechanism for safety, quality and efficacy of medicines sold in the country.

time to read

1 min

December 11, 2025

Chronicle Pharmabiz

Eli Lilly gets US FDA approval for Jaypirca

Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor.

time to read

1 mins

December 11, 2025

Chronicle Pharmabiz

Haryana DCA focuses on quality overhaul

THE Haryana drug control administration (DCA) is undertaking a major organizational overhaul focused on quality system upgrades and regulatory capacity building, particularly in response to the revised Schedule M norms.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

DoC seeks inputs on trade issues faced with Japan

THE Department of Commerce (DoC), under the Union Commerce Ministry, has sought inputs from the industry on specific issues being faced in pharma trade with Japan.

time to read

1 min

December 11, 2025

Chronicle Pharmabiz

AIOCD asks traders to strictly comply with ban on 35 FDCs

THE All India Organisation of Chemists and Druggists (AIOCD) has issued an urgent internal circular to all its state and Union territory trade bodies, demanding immediate and strict compliance with the ban on 35 fixed dose combinations (FDCs).

time to read

3 mins

December 11, 2025

Chronicle Pharmabiz

US FDA approves Bristol Myers Squibb's Breyanzi

Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

CN Water presents AQU@Sense MB

CN Water is now combining core water-system expertise with digital assurance has launched AQU@Sense which delivers microbial test results in under 30 minutes, replacing traditional 5 to 7 days culture based methods.

time to read

1 min

December 11, 2025

Chronicle Pharmabiz

Pharma logistics sees policy push as key catalyst for growth

INDIAN pharma's logistics sector is getting major boost from emerging policy support.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

Lack of financial aid, expertise mar MSME prospects to meet revised Sch M deadline

INDUSTRY experts have raised alarm that lack of financial assistance and guidance on technical expertise have marred pharma MSMEs’ prospects to comply with revised Schedule M guidelines of December 31, 2025.

time to read

2 mins

December 11, 2025

Listen

Translate

Share

-
+

Change font size